Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Rebif

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Rebif was produced by Merck KGaA.

Roche’s Ocrevus is first primary progressive MS drug in EU

Roche’s Ocrevus is first primary progressive MS drug in EU

One reason for the rapid take-up is clinical data showing that Ocrevus is more effective in relapsing MS than Merck KGaA’s beta interferon drug Rebif, as well as competitive

Novartis’ Extavia evades NICE restrictions on MS drugs

Novartis’ Extavia evades NICE restrictions on MS drugs Novartis’ Extavia evades NICE restrictions on MS drugs. But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s

Ocrevus off to a flying start as Roche raises 2017 forecasts

Ocrevus off to a flying start as Roche raises 2017 forecasts The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III

Roche sets disruptive price for new MS drug Ocrevus in US

Roche sets disruptive price for new MS drug Ocrevus in US Firm will significantly under cut rivals like Merck's Rebif. Roche has claimed US approval for its much anticipated new multiple sclerosis (MS) drug Ocrevus, and is pricing it at a ... market. It costs 20%-25% less than Rebif and other MS therapies

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics